HOME >> BIOLOGY >> NEWS
Millennium and Bayer industrializing drug discovery process through ongoing successful research alliance

More Than 70 disease-relevant validated drug targets moving in to or beyond screening in first two years of collaboration

CAMBRIDGE, Mass. and LEVERKUSEN, Germany, October 24, 2000 --Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) and Bayer AG today announced that they are currently moving more than 70 disease-relevant validated drug targets into high-throughput screening or lead identification in the first two years of their five-year research alliance. The alliance achieved these exceptional advances through joint efforts. The two companies collaborated to streamline the drug discovery process with Millennium industrializing the rapid identification, characterization and validation of target proteins and Bayer conducting large-scale high-throughput screening. This innovative approach to target discovery allows for the categorization of genes with disease relevance and is a key step in the process to enhance the productivity of drug discovery.

The alliance is centered on genomics research that identifies the composition and function of thousands of genes which carry instructions to make proteins the body needs to function. By integrating large-scale genetics, genomics, automation, informatics and drug discovery technologies, Millennium can rapidly search for disease-relevant targets that are promising for drug development. This resulting drug discovery platform, which effectively meets the needs of the research alliance with Bayer, serves all of Millenniums research programs, both internal and partnered, and contributes validated targets to the Companys own drug discovery pipeline.

With the aid of Bayers high-throughput robotic screening technology, the selected targets are incorporated into test systems to search for compounds that show promise for drug development. This screening process can test more than 200,000 such compounds daily.

The progress of the Millennium and Bayer alliance in its first tw
'"/>

Contact: Maureen Suda, Millennium Pharmaceuticals Inc.
617-551-2959
Porter Novelli
23-Oct-2000


Page: 1 2 3

Related biology news :

1. Millenniums LDP(PS)-341 inhibits growth and induces death of cancer cells, appears to overcome chemotherapy resistance
2. Science and Technology at the Millennium: Retrospect or Prospect Focus of AAAS Science and Technology Colloquium, April 11-13 in Washington, DC
3. Millennium and Wyeth-Ayerst announce the discovery of key potassium ion channel modulating proteins
4. Millennium and the Whitehead Institute identify novel protein important in fat absorption
5. Millennium Clones Diet-Induced Obesity Gene
6. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
7. New OHSU lab will speed drug discovery process
8. New discovery may help transplants survive
9. Genetic discovery could dramatically reduce need for liver transplants in children
10. Plant gene discovery could enhance plant growth, reduce fertilizer needs and phosphate pollution
11. Major scientific discovery in cancer research to be honored

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
Cached News: